Search results
All genres
Journal Article (33)
21.
Journal Article
19 (51), pp. 17584 - 17588 (2013)
Trapped in misbelief for almost 40 years: Selective synthesis of the four stereoisomers of mefloquine. Chemistry 22.
Journal Article
125 (6), pp. 795 - 813 (2013)
Anle138b: a novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and Parkinson's disease. Acta Neuropathologica 23.
Journal Article
52 (23), pp. 6047 - 6049 (2013)
The absolute configuration of (+)- and (-)-erythro-mefloquine. Angewandte Chemie International Edition 24.
Journal Article
50 (Supplement 1), pp. S38 - S44 (2012)
Chiral discrimination of amines by anisotropic NMR parameters using chiral polyacrylamide-based gels. Magnetic Resonance in Chemistry 25.
Journal Article
51 (3), pp. 329 - 337 (2011)
Cys-Ph-TAHA: A lanthanide binding tag for RDC and PCS enhanced protein NMR. Journal of Biomolecular NMR 26.
Journal Article
17 (34), pp. 9368 - 9376 (2011)
Dynamics of the glycosidic bond: Conformational space of lactose. Chemistry: A European Journal 27.
Journal Article
12 (22), pp. 5830 - 5840 (2010)
Shuttle DNP spectrometer with a two-center magnet. Physical Chemistry Chemical Physics 28.
Journal Article
17 (6), pp. 1025 - 1034 (2008)
The PIP2 binding mode of the C2 domains of rabphilin-3A. Protein Science 29.
Journal Article
129 (49), pp. 15114 - 15115 (2007)
Stereochemistry of sagittamide a from residual dipolar coupling enhanced NMR. Journal of the American Chemical Society 30.
Journal Article
282 (7), pp. 5015 - 5025 (2007)
The C2A-C2B linker defines the high affinity Ca2+ binding mode of rabphilin-3A. Journal of Biological Chemistry 31.
Journal Article
44 (Sp. Iss. S1), pp. S10 - S16 (2006)
Paramagnetic tagging of diamagnetic proteins for solution NMR. Magnetic Resonance in Chemistry 32.
Journal Article
8 (7), pp. 1275 - 1278 (2006)
Two new chiral EDTA-based metal chelates for weak alignment of proteins in solution. Organic Letters 33.
Journal Article
11 (11), pp. 3342 - 3348 (2005)
Convenient synthesis of multifunctional EDTA-based chiral metal chelates substituted with an S-mesylcysteine. Chemistry-A European Journal Conference Paper (7)
34.
Conference Paper
39 (Suppl), pp. 530 - 531 (2019)
In vitro evaluation of small molecule compounds as potential PET tracers targeting a-synuclein. 29th International Symposium on Cerebral Blood Flow, Metabolism and Function / 14th International Conference on Quantification of Brain Function with PET (BRAIN and BRAIN Pet), Yokohama, Japan, July 04, 2019 - July 07, 2019. Journal of Cerebral Blood Flow and Metabolism 35.
Conference Paper
116 (Suppl_1), p. 352A - 352A (2019)
Protein-drug interactions in the membrane: The small molecule Anle138b and its binding to alpha-synuclein oligomers. 63rd Annual Meeting of the Biophysical-Society, Baltimore, MD, March 02, 2019 - March 06, 2019. Biophysical Journal 36.
Conference Paper
The small molecule anle138b shows interaction with alpha-synuclein oligomers in phospholipid membranes. 62nd Annual Meeting of the Biophysical-Society, San Francisco, CA, February 17, 2018 - February 21, 2018. Biophysical Journal (Suppl), 3 Ed., p. 560a - 560a (2018)
37.
Conference Paper
110 (Suppl 1), 3 Ed., p. 420A - 420A (2016)
Effect of the novel amyloid inhibitor "anle145c" on aggregation of islet amyloid polypeptide and how it is modulated by membranes. 60th Annual Meeting of the Biophysical-Society, Los Angeles, CA, February 27, 2016 - March 02, 2016. Biophysical Journal 38.
Conference Paper
21 (Suppl. 1), p. 170 - 170 (2014)
The oligomer modulator anle138b is effective in the prodromal phase of a transgenic mouse model of Parkinson's disease. Joint Congress of European Neurology, Istanbul, Turkey, May 31, 2014 - June 03, 2014. European Journal of Neurology 39.
Conference Paper
70 (6), p. 505 - 505 (2011)
Causal therapy of prion and Parkinson's disease with novel inhibitors of protein aggregation. 87th Annual Meeting of the American Association of Neuropathologists, Seattle, WA, June 23, 2011 - June 26, 2011. Journal of Neuropathology and Experimental Neurology 40.
Conference Paper
26 (Supplement 2), p. S21 - S21 (2011)
Causal therapy of Parkinson's disease with anle138b, a novel protein aggregation inhibitor. 15th International Congress of Parkinsons Disease and Movement Disorders, Toronto, CANADA, 2011. Movement Disorders